The D- - phenotype is a genetic variant of the Rh blood group system. It expresses D antigen but lacks C, c, E and e antigens. In D- - phenotype, the RHCE coding region is extensively modified by RHD sequence replacement, nucleotide deletion or splice-site changes.
View Article and Find Full Text PDFBackground: Anti-Fy(a) has been implicated in hemolytic transfusion reactions. However, not all Fy(a-) patients develop anti-Fy(a) after transfusion with 1 unit of blood [Fy(a+)]. This study was designed to identify HLA-DRB1 alleles associated with a predisposition to Fy(a) immunization after blood transfusion.
View Article and Find Full Text PDFBackground: An EIA based on immune complex disassociation of nucleocapsid proteins of HCV has been developed to detect and quantify HCV core antigen.
Study Design And Methods: To evaluate whether this new assay (trak-C, Ortho Clinical Diagnostics) could be an alternative to NAT during the window period, its sensitivity in this context was assessed, and its performance was compared with that of a first-generation HCV core antigen assay dedicated to the blood screening (HCV core antigen ELISA). Studied populations included nine HCV RNA-positive, HCV antibody-negative blood donors and 23 hemodialysis patients who underwent an HCV seroconversion.
Background: Until 1990, HCV infection was common in transfused patients, resulting in more than 200,000 cases of posttransfusion hepatitis C in France alone. A molecular method that permits the investigation of posttransfusion hepatitis C infections is presented.
Study Design And Methods: Viral sequences in the envelope region of HCV were obtained for 12 pairs of blood recipients and their respective blood donors.
Background: The purpose of the study was to analyze serologic and molecular markers of the GB virus type C/hepatitis G virus (GBV-C/HGV) infection in voluntary blood donors from Southeastern France.
Study Design And Methods: Sera were tested for the presence of GBV-C/HGV RNA by reverse transcriptase-polymerase chain reaction and that of antibodies to the GBV-C/HGV E2 (anti-E2) antigen by an enzyme-linked immunosorbent assay. A first cohort (1660 blood donors) was tested prospectively and a second cohort (238 samples with hepatitis markers) was tested retrospectively.